Kusajili – Centralise les essais cliniques mondiaux

Résultat de votre recherche par promoteur : Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Femme Max 99 ans
Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited MAJ Il y a 4 ans

MLN0128 in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy. MLN0128 en combinación con Fulvestrant en mujeres con cáncer de mama avanzado o metastásico después de un tratamiento con inhibidores de la aromatasa - To compare the PFS of patients treated with the combination of fulvestrant+daily MLN0128 versus patients treated with single-agent fulvestrant. - To compare the PFS of patients treated with the comb...

Pays Aucun
Organes Aucun
Spécialités Aucune

unknown

Plus d'informations

Femme et Homme Max 99 ans
Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited MAJ Il y a 4 ans

The aim of the study is to provide patients with certain kinds of cancer continued access to the same drug they have received in a previous study, if they have benefited from the use of the drug. El objetivo de este estudio seguir ofreciendo a los pacientes acceso al mismo medicamento que han venido recibiendo en un estudio previo, si han tenido beneficio del uso del medicamento Primary Objective: To provide continued access of ixazomib and to evaluate the long-term safety profile of ixazomib. Objetivo Principal: Seguir ofreciendo acceso a ixazomib y evaluar la segurida...

Pays Aucun
Organes Aucun
Spécialités Aucune

unknown

Plus d'informations